Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Mirum Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
19.1
77.1
186
337
521
Research and development
43
81.6
131
107
103
141
186
Selling, general and administrative
59.2
89.1
146
202
257
General and administrative
11.8
22.7
59.2
Operating expenses
54.7
104
193
208
296
424
543
Operating income
-54.7
-104
-173
-131
-109
-87.6
-22.1
Interest expense
16
15.1
14.3
14.4
Interest income
2.23
1.56
0.37
3.86
13.7
13.8
12.7
Other non-operating income
-0.02
-0.19
-0.58
0.37
-2.82
1.21
2.37
Pre-tax income
-52.5
-103
-84
-142
-162
-86.9
-21.4
Income tax
0.02
0.01
0.04
-6.41
0.99
1.03
1.94
Net income
-52.6
-103
-84
-136
-163
-87.9
-23.4
EBITDA
-54.6
-104
-173
-128
-98.3
-64
2.11
EPS, basic
-4.58
-4.09
-2.77
-4.01
-4.00
-1.85
-0.47
EPS, diluted
-4.58
-4.09
-2.77
-4.02
-4.00
-1.85
-0.47
Shares, basic (weighted)
11.5
25.3
30.3
33.8
40.9
47.5
50.2
Shares, diluted (weighted)
11.5
25.3
30.3
34
40.9
47.5
50.2
Balance sheet
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
12
142
31.3
28
286
223
297
Short-term investments
105
89.7
125
124
0
57.8
86.6
Receivables
0
3.27
24
68
78.3
123
Inventory
0
1.51
5.57
22.3
22.4
24.9
Other current assets
2.7
4.53
5.27
8.95
10.9
11.8
18.1
Total current assets
119
236
167
190
388
393
550
Property, plant and equipment
1.37
1.29
0.98
0.91
0.71
1.14
1.86
Lease right-of-use assets
2.36
1.95
1.57
1.43
1.28
8.68
8.74
Intangible assets
0
18.7
59
253
250
261
Long-term investments
23.3
0
4.98
0
0
12.5
8.11
Other non-current assets
0.32
1.27
1.79
1.38
4.17
5.38
12
Total assets
147
241
295
353
647
671
843
Accounts payable
3.35
3.15
9.17
8.69
7.42
14.6
9.61
Accrued liabilities
9.33
13.4
30.7
54
78.5
112
196
Total current liabilities
13.1
18.5
42.6
64.7
87.1
127
206
Lease liabilities
3.25
2.63
1.9
1.26
0.62
7.97
7.52
Other non-current liabilities
0.04
0.03
0.02
4.53
3.85
2.51
5.01
Total liabilities
16.4
68.8
174
211
398
445
528
Paid-in capital
200
345
377
535
803
870
982
Retained earnings
-69.9
-173
-257
-393
-556
-644
-668
Other comprehensive income
0.13
0.08
-0.04
-0.22
1.64
-0.37
0.35
Shareholders' equity
130
172
120
142
249
226
315
Total equity
130
172
120
142
249
226
315
Total liabilities and equity
147
241
295
353
647
671
843
Shares outstanding
22.6
29.8
30.6
37
46.7
48.3
51.9
Cash flow statement
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-52.6
-103
-84
-136
-163
-87.9
-23.4
Depreciation and amortization
0.14
0.31
0.6
3.24
10.8
23.6
24.2
Stock-based compensation
6.07
12.6
23.1
27
35
48.4
71.4
Deferred income tax
0
-6.58
0
0
0
Change in receivables
0
-20.7
-44
-11.4
-48.1
Change in inventory
0
-0.5
-3.45
-0.97
-3.17
-8.45
Cash from operations
-39.4
-89.1
-133
-120
-70.9
10.3
55.8
Capital expenditures
-0.28
-0.23
-0.02
-0.28
-0.11
-0.99
-0.95
Acquisitions
0
0
-213
0
0
Purchases of investments
-152
-74.6
-198
-132
-27.3
-89
-97.4
Sales and maturities of investments
24.5
85.9
156
140
153
19.9
74.4
Cash from investing
-128
37.9
48.5
7.7
-107
-90.1
-24
Stock issued
0
0
21.3
14.5
0
0
Cash from financing
127
181
73.5
109
337
17.7
40.1
Net change in cash
-40
130
-10.7
-3.34
158
-63.4
75.2
Free cash flow
-39.6
-89.3
-133
-120
-71.1
9.33
54.9
Interest paid
0
0
6.82
12.7
12.7
Income taxes paid
0.02
0.01
0
0
0.13
1
2.16
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $89.70 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-134.9%
Operating income / revenue.
EBITDA margin
-130.7%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-138.7%
Pre-tax income / revenue.
Net margin
-139.2%
Net income / revenue.
FCF margin
-37.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-36.8%
Cash from operations / revenue.
Return on assets (ROA)
-82.3%
Net income / average total assets.
R&D / revenue
45.7%
Research and development expense / revenue.
SG&A / revenue
50.8%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
16.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.2%
Capital expenditures / revenue.
D&A / revenue
4.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
54.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
89.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y
440.7%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
488.0%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
39.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
30.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
12.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
25.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
33.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
28.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
5.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
13.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
14.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.86x
Current assets / current liabilities.
Quick ratio
2.62x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.97x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$9.75
Revenue / diluted weighted shares.
FCF per share
-$3.61
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.59
Cash from operations / diluted weighted shares.
Book value per share
-$0.16
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
9.42x
Market cap / revenue.
EV/Sales
8.71x
Enterprise value / revenue.
FCF yield
-3.9%
Free cash flow / market cap.
Earnings yield
-14.8%
Net income / market cap (the inverse of P/E).
What was Mirum Pharmaceuticals, Inc.'s revenue in fiscal 2025?
Mirum Pharmaceuticals, Inc. reported revenue of $521.3M for fiscal 2025, 54.7% higher than the year before.
Was Mirum Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $23.4M.
How much free cash flow did Mirum Pharmaceuticals, Inc. generate in fiscal 2025?
Cash from operations of $55.8M minus capital expenditures of $954.0K left free cash flow of $54.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.